SCHEMBL3157516

SCHEMBL3157516

Nc1ccc(S(=O)(=O)NCS(=O)(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.69
CYP3A4 P08684 1/20 0.59
CA1 P00915 11/20 0.58
CA2 P00918 11/20 0.58
CA12 O43570 10/20 0.58
CA9 Q16790 10/20 0.58
MMP1 P03956 1/20 0.57
MMP2 P08253 1/20 0.57
MMP9 P14780 1/20 0.57
MMP8 P22894 1/20 0.57
MMP13 P45452 1/20 0.57
CA6 P23280 2/20 0.53
CA5A P35218 2/20 0.53
CA7 P43166 2/20 0.53
CA5B Q9Y2D0 2/20 0.53
CA4 P22748 1/20 0.53
TSHR P16473 3/20 0.52
ALDH1A1 P00352 1/20 0.52
NT5E P21589 1/20 0.52
PRMT1 Q99873 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trolamine SCHEMBL339125 0.87 CYP2D6 (0.55) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL11516144 0.81 CYP2D6 (1.00) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL10790350 0.80 ALDH1A1 (0.62) CA1CA2CA12CA9MMP1
SCHEMBL11520559 0.79 CYP2D6 (0.81) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL11682917 0.79 CYP2D6 (0.81) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL14355362 0.78 ALDH1A1 (0.48) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL2563975 0.77 CYP3A4 (0.70) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL30380602 0.77 CYP2D6 (0.68) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL923761 0.76 CA1 (0.72) CYP2D6CYP3A4CA1CA2CA12
SCHEMBL1228868 0.76 MMP1 (0.67) CYP2D6CYP3A4CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0741570-B1 PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS SEARLE & CO (US) 2003-05-07 EP claimed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
CN-103059165-B Polysaccharide acylate and preparation method thereof BENGBU BBCA TUSHAN PHARM CO 2015-04-29 CN disclosed
CN-103059165-A Polysaccharide acylate and preparation method thereof BENGBU BBCA TUSHAN PHARM CO 2013-04-24 CN disclosed
CN-101784274-A The method and composition that suppresses edema factor and adenyl cyclase MISSION PHARMA CO 2010-07-21 CN disclosed
EP-0852499-B1 THERAPEUTIC AZIDE COMPOUNDS UNIV GEORGIA RES FOUND (US) 2010-03-03 EP disclosed
US-7122198-B1 Fast dissolving composition with prolonged sweet taste PANACEA BIOTEC LIMITED (IN) 2006-10-17 US disclosed
EP-1644046-A2 CONJUGATED COMPLEMENT CASCADE INHIBITORS Ortho-McNeil Pharmaceutical, Inc. (US) 2006-04-12 EP disclosed
US-6949521-B2 Therapeutic azide compounds THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2005-09-27 US disclosed
US-20050043253-A1 Use of wound healing compositions for prevention of infections and allergies COOK BRADLEY R (US) 2005-02-24 US disclosed
US-6271212-B1 MIXTURE WITH CARRIER UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. 2001-08-07 US disclosed
WO-2001039749-A2 FAST DISSOLVING COMPOSITION WITH PROLONGED SWEET TASTE PANACEA BIOTEC LIMITED (IN) 2001-06-07 WO disclosed
EP-0852499-A1 THERAPEUTIC AZIDE COMPOUNDS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1998-07-15 EP disclosed
WO-1998002164-A1 TREATMENT OF EQUINE PROTOZOAL MYELOENCEPHALITIS MORTAR & PESTLE VETERINARY PHARMACY, INC. (US) 1998-01-22 WO disclosed
WO-1997009052-A1 THERAPEUTIC AZIDE COMPOUNDS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1997-03-13 WO disclosed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP disclosed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP disclosed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO disclosed